St. Tammany Health System added to its diagnostic arsenal as the first Northshore health system to offer a powerful new MRI solution for targeted biopsy of the prostate. Through purchase of the UroNav fusion biopsy system, STHS offers more accurate biopsy for patients with elevated and/or rising PSA levels.
Targeted MR/ultrasound biopsy is poised to become the new standard in prostate care. UroNav fuses pre-biopsy MR images of the prostate with ultrasound images in real time, providing exceptional delineation of the prostate and suspicious lesions.
After a patient has undergone a prostate MRI, STHS radiologists utilize DynaCAD for Prostate to quickly visualize and evaluate suspicious lesions.
“This is a significant advancement compared to the conventional approach, which may have been less precise,” Jack Khashou, vice president of St. Tammany Cancer Center said. “The UroNav fusion biopsy system uses this critical diagnostic information to provide highly skilled local urologists with a targeted approach to prostate biopsy. The fusion of MR and ultrasound images through UroNav gives our urologists the ability to offer their patients an alternative to remaining in an uncertain state of diagnosis after a prostate exam or prior negative ultrasound biopsy.”
Other than skin cancer, prostate cancer has become the most common form of cancer in American men and the second-leading cause of cancer death in this population, according to American Cancer Society, which finds one in every six men will be diagnosed with prostate cancer during his lifetime.